They are medications that mimic GLP-1s, which are the main hormone involved in regulating glucose, signaling hunger, and balancing metabolic rate
When someone applies for life insurance after losing weight on GLP-1 medications, underwriters see what looks like a healthy person with: Normal BMI Improved blood pressure Better cholesterol levels Lower HbA1c levels But here's the catch: Research from the landmark STEP 1 trial extension shows that participants regain approximately two-thirds of their prior weight loss within one year of stopping semaglutide (Wilding et al., 2022)
Constipation affects a significant portion of users and can range from mild to severe
However, the combination of GLP-1 receptor agonists with DPP-4 inhibitors have not demonstrated clinically significant additional benefits [116]
Women whose BMI qualifies them for the weight management indication often have an easier time obtaining coverage, while normal-weight women with PCOS and insulin resistance may face more barriers
Briefly, mice were fasted for five hours in fresh cages with ad libitum access to drinking water
